RECRUITING

Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Description

The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.

Study Overview

Study Details

Study overview

The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.

Collection of Whole Blood Specimens from Pregnant Women At Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted from Maternal Plasma

Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Condition
Down Syndrome
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama Birmingham, Birmingham, Alabama, United States, 35294

Los Angeles

Cedars-Sinai Medical Center, Los Angeles, California, United States, 90048

San Diego

Sharp-Rees Stealy Medical Group, San Diego, California, United States, 92101

San Diego

UCSD, San Diego, California, United States, 92121

San Diego

Women's Health Care Research, San Diego, California, United States, 92123

San Diego

Specialty Obstetrics of San Diego, San Diego, California, United States, 92130

Chicago

Reproductive Genetics Institute, Chicago, Illinois, United States, 60602

Iowa City

University of Iowa Health Care, Iowa City, Iowa, United States, 52242

Detroit

Henry Ford Hospital, Detroit, Michigan, United States, 48202

Grand Rapids

Spectrum Health, Grand Rapids, Michigan, United States, 49503

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * pregnant between 10 and 22 weeks gestation
  • * 18 years of age or older
  • * provides signed and dated informed consent
  • * subject is at increased risk for fetal aneuploidy
  • * subject is willing to undergo a CVS and/or amniocentesis procedure for the purpose of genetic analysis
  • * subject agrees to provide the genetic results of the invasive procedure
  • * Fetal demise at time of specimen sampling
  • * Previous sample donation under this protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sequenom, Inc.,

Daniel Grosu, MD, STUDY_DIRECTOR, Sequenom, Inc.

Study Record Dates

2026-03